Study on the Efficacy of Cefoperazone-Sulbactam and Piperacillin-Tazobactam in Managing Severe Community-Acquired Pneumonia

Background: Severe community-acquired pneumonia is associated with high illness and mortality.Cefoperazone-sulbactam has broad-spectrum activity and may serve as an alternative to piperacillin-tazobactam, but comparative evidence in severe community-acquired pneumonia (CAP) is limited.Methods: This observational, prospective cohort study aimed to compare the efficacy, safety, and outcomes of cefoperazonesulbactam and piperacillin-tazobactam in treating severe CAP.Adult patients diagnosed with severe SEVERE CAP were assigned to treatment groups based on physician discretion, and the study assessed clinical cure rates, microbiological eradication, adverse drug reactions, and 30-day mortality.Sputum and blood cultures were analysed for pathogen resistance.The study continued until the required sample size was met, with a focus on treatment efficacy and safety. Results:The study found that the CEFOPERAZONE-SULBACTAM and PIPERACILLIN-TAZOBACTAM groups had similar demographic characteristics, with no significant differences in age, BMI, or sex distribution.Blood tests showed no significant differences in WBC, RBC, or haemoglobin levels.However, the CEFOPERAZONE-SULBACTAM group had higher neutrophils (64.1 vs. 50.5)and lower eosinophils (1.74 vs. 3.1), while the PIPERACILLIN-TAZOBACTAM group had higher lymphocytes (39.84 vs. 29.94).The PIPERACILLIN-TAZOBACTAM group achieved sputum negativity faster (10.43 vs. 12.93 days).Adverse reactions like nausea and vomiting were more frequent in the PIPERACILLIN-TAZOBACTAM group, whereas urticaria and anaemia were more common in the CEFOPERAZONE-SULBACTAM group. Conclusion:The study has concluded that both cefoperazone-sulbactam and piperacillin-tazobactam demonstrated similar efficacy in treating patients, with piperacillin-tazobactam achieving sputum negativity more quickly.